Skip to content
Screener

Eton Pharmaceuticals, Inc. ETON Q4 2025 Annual earnings

Reported March 19, 2026 · After market close

Revenue$21.3MBeat by $1.3M
EPS$0.05Miss by $0.07
Revenue estimate$20.0M
EPS estimate$0.12

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$42.0M
EPS estimate$0.34

Financials

Q4 2025

Income statement

See full
Revenue$21.3M+82.7%
Gross profit$13.1M+102%

Balance sheet

See full
Cash & equivalents$25.9M+73.7%
Total debt$31.1M+3.6%
Total equity$26.2M+7.1%
Total assets$92.1M+21.0%

Cash flow

See full
CapEx$49.0K+308%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$453.48M+30.7%
Enterprise value$458.63M+26.7%
P/S5.7×-3.2×

Profitability

See full
Gross margin53.5%-6.6pp

Returns & leverage

See full
Debt / equity1.2×0.0×
Current ratio1.6×-0.5×

FAQ

When did Eton Pharmaceuticals, Inc. report Q4 2025 earnings?
Eton Pharmaceuticals, Inc. (ETON) reported Q4 2025 earnings on March 19, 2026 after market close.
What were Eton Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Eton Pharmaceuticals, Inc. reported revenue of $21.3M and eps of $0.05 for Q4 2025.
Did Eton Pharmaceuticals, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $20.0M by $1.3M. EPS missed the consensus estimate of $0.12 by $0.07.
How did Eton Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 82.7% from $11.6M a year earlier.
Where can I find Eton Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001437749-26-009060) and the 10-K periodic report (0001437749-26-009059) directly on SEC EDGAR. The filing index links above go to sec.gov.